Dr. Ward has spent the past 16 years developing mouse models to help identify the cellular and molecular mechanisms underlying inflammatory skin disease and its associated comorbidities, including atherothrombosis, psoriatic arthritis, inflammatory bowel disease, and depression. Read this article to see what Dr. Ward is currently investigating. Read now
This report provides a meeting summary and key points of presentations and discussions held during IPC's 2020 virtual Think Tank. Read now
This report provides a meeting summary and key points of presentations and discussions held during IPC's 2019 Think Tank. Read now
This report provides a meeting summary and key points of presentations and discussions held during IPC's 2018 Think Tank. Download
The IPC contributed to the the WHO Global Report on Psoriasis (2016) and subsequently launched the Global Psoriasis Atlas project in April 2017. Download
now available COVID-19 Psoriasis Resource Center Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve explore now
Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve
Latest news European Commission approves SKYRIZI® for psoriatic arthritis in adultsNovember 22, 2021The European Commission has approved SKYRIZI® for the treatment of active psoriatic arthritis in adults. Focus on Psoriasis – A Report from the 2021 Virtual EADV CongressNovember 18, 2021The European Academy of Dermatology and Venerelogy 30th Annual Congress (EADV) was packed with science and clinical practice updates. You can download the full report or read a brief look at some of the highlights. PsoProtect Registry Data UpdateNovember 04, 2021PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,272 cases. Update on spesolimab for generalized pustular psoriasisNovember 02, 2021The European Medicines Agency (EMA) has accepted to review Boehringer Ingelheim’s marketing authorization application (MAA) for spesolimab to treat flares in generalised pustular psoriasis (GPP). More News